Ticlopidine pretreatment before coronary stenting is associated with sustained decrease in adverse cardiac events: data from the Evaluation of Platelet IIb/IIIa Inhibitor for Stenting (EPISTENT) trial - Steinhubl,S.R.; Ellis,S.G.; Wolski,K.; Lincoff,A.M.; Topol,E.J. (Circulation, 2001)